Today: 19 April 2026
Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS
15 January 2026
2 mins read

Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS

New York, January 15, 2026, 11:05 EST

  • Boston Scientific struck a deal to acquire Penumbra for roughly $14.5 billion, sending Penumbra’s shares up
  • Verizon handed out $20 credits following a 10-hour wireless outage that caught federal attention
  • Goldman Sachs and Morgan Stanley saw their quarterly profits rise, driven by increased dealmaking and trading activity

Boston Scientific (BSX) struck a deal to acquire Penumbra (PEN) for roughly $14.5 billion on Thursday, drawing attention to the medical device sector. This move came amid Verizon’s (VZ) ongoing outage issues and new earnings reports from Goldman Sachs (GS) and Morgan Stanley (MS).

The Penumbra deal marks the first significant healthcare takeover of 2026, arriving just as investors seek confirmation that large mergers are making a comeback. With borrowing costs down and regulators taking a softer stance, Wall Street has been buzzing—now this deal puts those hopes to the test.

Bank earnings reinforced the trend. Goldman and Morgan Stanley flagged stronger deal flow. At the same time, Verizon’s network disruption highlighted how fast operational slip-ups can spiral into regulatory scrutiny and customer credits.

Boston Scientific announced it will pay $374 per Penumbra share in a mix of cash and stock. CEO Mike Mahoney described Penumbra as “a well-established company” and said the deal taps into “new, fast-growing segments” within vascular care. Penumbra’s CEO Adam Elsesser highlighted the company’s focus on “deep innovation for complex diseases.” https://news.bostonscientific.com/2026-01-…

The deal prices Penumbra about 19% above its last closing price, sending its shares up over 12% early Thursday. Truist analyst Richard Newitter noted the acquisition plugs a hole in Boston Scientific’s neurovascular portfolio, bringing it back into brain clot-removal devices—a business it exited when it sold to Stryker more than ten years ago.

Verizon announced a $20 credit for hundreds of thousands of customers affected by a 10-hour outage on Wednesday, attributing the disruption to a software glitch. The company insisted the issue was not the result of a cyberattack and advised users still experiencing problems to restart their devices. The Federal Communications Commission said it will investigate the outage.

Goldman Sachs posted fourth-quarter profits that topped Wall Street expectations, driven by a boost in dealmaking and stronger trading. “The stock has been on a tear and already discounted these results,” said Gerard Cassidy of RBC Capital Markets, as Goldman shares slipped in premarket action. https://www.reuters.com/business/finance/g…

Morgan Stanley beat forecasts, thanks largely to a 47% surge in investment banking revenue, which hit $2.41 billion. CFO Sharon Yeshaya told Reuters she’s seeing “an accelerating pipeline in M&A and IPOs.” CEO Ted Pick highlighted geopolitical risks but emphasized the bank’s intent to remain “patient” on acquisitions. https://www.reuters.com/business/finance/m…

Together, the updates highlighted two types of catalysts investors often track. One involves deal activity — who’s acquiring whom, and what that signals about growth and confidence. The other covers the messier issues, such as outages and complaints, that can quickly draw regulatory attention.

AST SpaceMobile (ASTS) remained in focus, as investors kept an eye on the satellite-to-smartphone angle gaining traction in retail circles. A recent Motley Fool piece highlighted AST as a risky play, emphasizing that success in space-based cellular broadband hinges on execution, not just bold claims.

AST says its BlueBird satellites aim to deliver 4G and 5G service straight to standard smartphones. The company claims partnerships with over 50 mobile network operators, reaching nearly 3 billion subscribers. Founder and CEO Abel Avellan said they have a “fully-funded plan” to launch 45 to 60 satellites by 2026, with deployments scheduled through 2025 and 2026. https://ast-science.com/partners/ https://www.sec.gov/Archives/edgar/data/17…

Today’s major headlines come with caveats. Boston Scientific has to clear closing hurdles and brace for a deal that’s likely to dilute adjusted earnings per share in its first full year post-close. Verizon is under FCC scrutiny, with ongoing risks of customer churn. Banks’ deal flow hinges on markets remaining open and investor confidence staying intact. For AST and other space-telecom names, launch timetables, spectrum approvals, and funding requirements can shift abruptly — and the stocks often react accordingly.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Critical Metals stock slips despite $1.5B Saudi rare-earth JV term sheet as shareholder sale looms
Previous Story

Critical Metals stock slips despite $1.5B Saudi rare-earth JV term sheet as shareholder sale looms

Intuitive Surgical stock slips again as 2026 da Vinci outlook keeps pressure on ISRG
Next Story

Intuitive Surgical stock slips again as 2026 da Vinci outlook keeps pressure on ISRG

Go toTop